Evogene (EVGN) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Evogene’s subsidiary, Lavie Bio, faces a strategic shift as Corteva Agriscience terminates their licensing agreement for bio-fungicide candidates. Despite this setback, Lavie Bio will retain rights to the technology and plans to advance its bio-fungicide pipeline independently. Other collaborations between Lavie Bio and Corteva remain unaffected.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
